|Mr. Michael B. Jebsen||Interim CEO, Pres & CFO||471.25k||N/A||1971|
|Mr. John P. Kelley||Consultant||720.25k||N/A||1954|
|Ms. Nancy J. M. Hecox||Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Maria Isabel Tomargo||Assistant VP of Marketing & Sales||N/A||N/A||N/A|
|Mr. Robert F. Diegelmann Ph.D.||Head of New Wound Care Division||N/A||N/A||N/A|
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Tenax Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.